Literature DB >> 26719329

Deubiquitylase Inhibition Reveals Liver X Receptor-independent Transcriptional Regulation of the E3 Ubiquitin Ligase IDOL and Lipoprotein Uptake.

Jessica Kristine Nelson1, Emma Clare Laura Cook1, Anke Loregger1, Marten Anne Hoeksema1, Saskia Scheij1, Igor Kovacevic2, Peter Lodewijk Hordijk2, Huib Ovaa3, Noam Zelcer4.   

Abstract

Cholesterol metabolism is subject to complex transcriptional and nontranscriptional regulation. Herein, the role of ubiquitylation is emerging as an important post-translational modification that regulates cholesterol synthesis and uptake. Similar to other post-translational modifications, ubiquitylation is reversible in a process dependent on activity of deubiquitylating enzymes (DUBs). Yet whether these play a role in cholesterol metabolism is largely unknown. As a first step to test this possibility, we used pharmacological inhibition of cellular DUB activity. Short term (2 h) inhibition of DUBs resulted in accumulation of high molecular weight ubiquitylated proteins. This was accompanied by a dramatic decrease in abundance of the LDLR and attenuated LDL uptake into hepatic cells. Importantly, this occurred in the absence of changes in the mRNA levels of the LDLR or other SREBP2-regulated genes, in line with this phenotype being a post-transcriptional event. Mechanistically, we identify transcriptional induction of the E3 ubiquitin ligase IDOL in human and rodent cells as the underlying cause for ubiquitylation-dependent lysosomal degradation of the LDLR following DUB inhibition. In contrast to the established transcriptional regulation of IDOL by the sterol-responsive liver X receptor (LXR) transcription factors, induction of IDOL by DUB inhibition is LXR-independent and occurs in Lxrαβ(-/-) MEFs. Consistent with the role of DUBs in transcriptional regulation, we identified a 70-bp region in the proximal promoter of IDOL, distinct from that containing the LXR-responsive element, which mediates the response to DUB inhibition. In conclusion, we identify a sterol-independent mechanism to regulate IDOL expression and IDOL-mediated lipoprotein receptor degradation.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  E3 ubiquitin ligase; IDOL; LDLR; LXR; cholesterol metabolism; deubiquitylation (deubiquitination); lipoprotein receptor; nuclear receptor; post-transcriptional regulation

Mesh:

Substances:

Year:  2015        PMID: 26719329      PMCID: PMC4813502          DOI: 10.1074/jbc.M115.698688

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

Review 1.  The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein.

Authors:  H H Hobbs; D W Russell; M S Brown; J L Goldstein
Journal:  Annu Rev Genet       Date:  1990       Impact factor: 16.830

2.  Immortalized human hepatocytes as a tool for the study of hepatocytic (de-)differentiation.

Authors:  I J Schippers; H Moshage; H Roelofsen; M Müller; H S Heymans; M Ruiters; F Kuipers
Journal:  Cell Biol Toxicol       Date:  1997-07       Impact factor: 6.691

3.  An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha.

Authors:  B A Janowski; P J Willy; T R Devi; J R Falck; D J Mangelsdorf
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

Review 4.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

5.  The LDL receptor locus in familial hypercholesterolemia: multiple mutations disrupt transport and processing of a membrane receptor.

Authors:  H Tolleshaug; K K Hobgood; M S Brown; J L Goldstein
Journal:  Cell       Date:  1983-03       Impact factor: 41.582

6.  SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene.

Authors:  C Yokoyama; X Wang; M R Briggs; A Admon; J Wu; X Hua; J L Goldstein; M S Brown
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

7.  Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression.

Authors:  Brandee L Wagner; Annabel F Valledor; Gang Shao; Chris L Daige; Eric D Bischoff; Mary Petrowski; Kristen Jepsen; Sung Hee Baek; Richard A Heyman; Michael G Rosenfeld; Ira G Schulman; Christopher K Glass
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

8.  Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha.

Authors:  D J Peet; S D Turley; W Ma; B A Janowski; J M Lobaccaro; R E Hammer; D J Mangelsdorf
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

9.  SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element.

Authors:  X Hua; C Yokoyama; J Wu; M R Briggs; M S Brown; J L Goldstein; X Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

10.  On terminal alkynes that can react with active-site cysteine nucleophiles in proteases.

Authors:  Reggy Ekkebus; Sander I van Kasteren; Yogesh Kulathu; Arjen Scholten; Ilana Berlin; Paul P Geurink; Annemieke de Jong; Soenita Goerdayal; Jacques Neefjes; Albert J R Heck; David Komander; Huib Ovaa
Journal:  J Am Chem Soc       Date:  2013-02-15       Impact factor: 15.419

View more
  9 in total

1.  Effects of statins on the inducible degrader of low-density lipoprotein receptor in familial hypercholesterolemia.

Authors:  Melody Lok-Yi Chan; Sammy Wing-Ming Shiu; Ching-Lung Cheung; Anskar Yu-Hung Leung; Kathryn Choon-Beng Tan
Journal:  Endocr Connect       Date:  2022-06-15       Impact factor: 3.221

Review 2.  LXR Regulation of Brain Cholesterol: From Development to Disease.

Authors:  Rebecca Courtney; Gary E Landreth
Journal:  Trends Endocrinol Metab       Date:  2016-04-21       Impact factor: 12.015

3.  Foiling IDOL to Help Control Cholesterol.

Authors:  Andrew J Brown; Joanne Hsieh
Journal:  Circ Res       Date:  2016-02-05       Impact factor: 17.367

4.  Peroxisomal abnormalities in the immortalized human hepatocyte (IHH) cell line.

Authors:  Femke C C Klouwer; Janet Koster; Sacha Ferdinandusse; Hans R Waterham
Journal:  Histochem Cell Biol       Date:  2016-12-24       Impact factor: 4.304

5.  Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.

Authors:  Li Yang; Jing Chen; Xiaoyan Han; Enfan Zhang; Xi Huang; Xing Guo; Qingxiao Chen; Wenjun Wu; Gaofeng Zheng; Donghua He; Yi Zhao; Yang Yang; Jingsong He; Zhen Cai
Journal:  Protein Cell       Date:  2018-02-13       Impact factor: 14.870

6.  Taking One Step Back in Familial Hypercholesterolemia: STAP1 Does Not Alter Plasma LDL (Low-Density Lipoprotein) Cholesterol in Mice and Humans.

Authors:  Natalia Loaiza; Merel L Hartgers; Aldo Grefhorst; Jan Albert Kuivenhoven; Laurens F Reeskamp; Jan-Willem Balder; Antoine Rimbert; Venetia Bazioti; Justina C Wolters; Maaike Winkelmeijer; Hans P G Jansen; Geesje M Dallinga-Thie; Andrea Volta; Nicolette Huijkman; Marieke Smit; Niels Kloosterhuis; Mirjam Koster; Arthur F Svendsen; Bart van de Sluis; G Kees Hovingh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-01-30       Impact factor: 8.311

Review 7.  TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance.

Authors:  Flaviana Marzano; Mariano Francesco Caratozzolo; Graziano Pesole; Elisabetta Sbisà; Apollonia Tullo
Journal:  Biomedicines       Date:  2021-02-27

8.  IDOL gene variant is associated with hyperlipidemia in Han population in Xinjiang, China.

Authors:  Dilare Adi; Jialin Abuzhalihan; Ying-Hong Wang; Gulinaer Baituola; Yun Wu; Xiang Xie; Zhen-Yan Fu; Yi-Ning Yang; Xiang Ma; Xiao-Mei Li; Bang-Dang Chen; Fen Liu; Yi-Tong Ma
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

Review 9.  Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System.

Authors:  Ruqaia Abbas; Sarit Larisch
Journal:  Cells       Date:  2021-12-08       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.